Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2023
New Parkinson's disease treatment added to PBS
1 February 2023 - From 1 February, Australians with Parkinson’s disease will have access to a new medicine on the PBS. ...
Posted by Michael Wonder on 31 Jan 2023
A watershed year for biosimilars — if regulators and policy makers step up
31 January 2023 - 31 January is set to mark the start of a watershed year for the biosimilars industry ...
Posted by Michael Wonder on 31 Jan 2023
Schedule of Pharmaceutical Benefits - 1 February 2023
1 February 2023 - The February 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jan 2023
New Zealand Pharmaceutical Schedule - 1 February 2023
1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Jan 2023
Amjevita (adalimumab-atto), first biosimilar to Humira, now available in the United States
31 January 2023 - Four years of real world experience in more than 300,000 patients and over 60 countries. ...
Posted by Michael Wonder on 31 Jan 2023
Call for Enhertu to be registered on Pharmaceutical Benefits Scheme
31 January 2023 - Sarah Lee has been forced to use her super and life insurance to pay for the treatment. ...
Posted by Michael Wonder on 23 Jan 2023
Mum's push for cystic fibrosis treatment to be subsidised for children under 12
23 January 2023 - Mila was diagnosed with cystic fibrosis aged just one, after experiencing lung failure in hospital, and ...
Posted by Michael Wonder on 22 Jan 2023
Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s
22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...
Posted by Michael Wonder on 21 Jan 2023
RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023
20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's ...
Posted by Michael Wonder on 21 Jan 2023
China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List
18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the ...
Posted by Michael Wonder on 21 Jan 2023
Assessing and extending California’s insulin manufacturing initiative
19 January 2023 - Set against the backdrop of current debates about lowering drug costs, lowering the price of insulin—a lifesaving ...
Posted by Michael Wonder on 19 Jan 2023
Drugs added to reimbursement list
19 January 2023 - China will add 111 drugs to its national medical reimbursement list this year, with a focus ...
Posted by Michael Wonder on 19 Jan 2023
Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications
18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in ...
Posted by Michael Wonder on 19 Jan 2023
Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of Tascenso ODT (fingolimod)
17 January 2023 - Tascenso ODT is now approved by the US FDA as a bioequivalent to Gilenya (fingolimod hydrochloride), for ...
Posted by Michael Wonder on 18 Jan 2023
Zai Lab announces inclusion of Qinlock (ripretinib) and Nuzyra (omadacycline) in China’s National Reimbursement Drug List
18 January 2023 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...